Economic evaluation of the familial cancer programme in Western Australia: Predictive genetic testing for familial adenomatous polyposis and hereditary non-polyposis colorectal carcinoma

Community Genetics

Volumn 9, Issue 2, 2006, Pages 98-106

  Breheny, N ^a,b   Geelhoed, E ^a   Goldblatt, J ^a   Ee, H ^a   O'Leary, P ^a  

^a DEPARTMENT OF HEALTH   (Australia)

^b Apartment 926   (United States)

Author keywords

Colorectal cancer; Cost effectiveness; Familial adenomatous polyposis; Familial cancer; Genetic testing; Hereditary non polyposis colorectal carcinoma; Screening; Surveillance

Indexed keywords

ADENOMATOUS POLYP; ADULT; AGED; ARTICLE; AUSTRALIA; CANCER RISK; COLORECTAL CANCER; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; FAMILIAL CANCER; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENETIC COUNSELING; GENETIC PROCEDURES; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; SCHOOL CHILD;

ADENOMATOUS POLYPOSIS COLI; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; MUTATION; WESTERN AUSTRALIA;

EID: 33645700916     PISSN: 14222795     EISSN: None     Source Type: Journal    
DOI: 10.1159/000091487     Document Type: Article

References (26)

1. Friedl W, Caspari R, Sengteller M, Uhlhaasa S, Lambertib C, Jungckb M, Kadmonc M, Wolfd M, Fahnensticka J, Gebertc J, Mösleine G, Mangolda E, Proppinga P: Can APC mutation analysis contribute to therapeutic decisions in familial adenomatous polyposis? Experience from 680 FAP families. Gut 2001;48:515-521.
2. Aarnio M, Mecklin JP, Aaltonen LA, Nystrom-Lahti M, Jarvinen HJ: Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer 1995;64:430-433.
3. Modell B, Kuliev AM, Wagner M: Community genetics services in Europe: report on a survey. Copenhagen, WHO Regional Publications, 1991.
4. Renkonen-Sinisalo L, Aarnio M, Mecklin JP, Jarvinen HJ: Surveillance improves survival of colorectal cancer in patients with hereditary nonpolyposis colorectal cancer. Cancer Detect Prev 2000;24:137-142.
5. Syngal S, Weeks JC, Schrag D, et al: Benefits of colonoscopic surveillance and prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer mutations. Ann Intern Med 1998;129:787-796.
6. Heiskanen I, Luostarinen T, Jarvinen H: Impact of screening examinations on survival in familial adenomatous polyposis. Scand J Gastroenterol 2000;35:1284-1287.
7. Jarvinen H, Aarnio M, Mustonen H, et al: Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 2000;118:829-834.
8. Vasen HF, Van Ballegooijen M, Buskens E, et al: A cost-effectiveness analysis of colorectal screening for hereditary nonpolyposis colorectal carcinoma gene carriers. Cancer 1998;82:1632-1637.
9. Stanley AJ, Gaff CL, Aittomaki AK, et al: Value of predictive genetic testing in management of hereditary non-polyposis colorectal cancer (HNPCC). Med J Aust 2000;172:313-316.
10. Grann VR, Whang W, Jacobson JS, et al: Benefits and costs of screening Ashkenazi Jewish women for BRCA1 and BRCA2. J Clin Oncol 1999;17:494-500.
11. Grann VR, Jacobson JS, Thomason D, et al: Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis. J Clin Oncol 2002;20:2520-2529.
12. NHMRC: Clinical Practice Guidelines - Familial Aspects of Cancer: A Guide to Clinical Practice. Canberra, National Health and Medical Research Council, 1999.
13. NHMRC: Clinical Practice Guidelines: The prevention, Early Detection and Management of Colorectal Cancer. Canberra, National Health and Medical Research Council, 1999.
14. Australian Institute of Health and Welfare: Health Expenditure in Australia 2001-02. Canberra, Australian Institute of Health and Welfare. 2003, AIHW Cat No HWE 24.
15. NHMRC: Clinical Practice Guidelines for the management of Early Breast Cancer, ed 2. Canberra, National Health and Medical Research Council, 2001.
16. Australian Institute of Health and Welfare: Australian Institute of Health and Welfare Disease Expenditure Database - unpublished.
17. Lynch HT, de la Chappelle A: Hereditary colorectal cancer. N Engl J Med 2003;348:919-932.
18. Australian Institute of Health and Welfare: Cancer in Australia 2000. Canberra, Australian Institute of Health and Welfare & Australasian Association of Cancer Registries, 2003.
19. Green J, O'Driscoll M, Barnes A., Maher ER, Bridge P, Shields K, Parfrey PS: Impact of gender and parent of origin on the phenotypic expression of hereditary nonpolyposis colorectal cancer in a large Newfoundland kindred with a common MSH2 mutation. Dis Colon Rectum 2002;45:1223-1232.
20. Bisgaard M, Fenger K, Bulow S, Niebuhr E, Mohr J: Familial adenomatous polyposis (FAP): frequency, penetrance, and mutation rate. Hum Mutat 1994;3:121-125.
21. Cromwell DM: Cost analysis of alternative approaches to colorectal screening in familial adenomatous polyposis. Gastroenterology 1998;114:893-901.
22. Col NF: The use of gene tests to detect hereditary predisposition to chronic disease: is cost-effectiveness analysis relevant? Med Decis Making 2003;23:441-448.
23. Kasparian NA, Meiser B, Job RFS, Hughes TMD, Mann GJ: 'Better the devil you know?' Understanding individuals' attitudes toward, and interest in genetic testing for melanoma susceptibility. in: Familial Cancer 2003: Research and Practice. Conference Proceedings, Queensland 2003.
24. Marteau T, Lerman C: Genetic risk and behavioural change. BMJ 2001;322:1056-1059.
25. Eisen A, Weber BL: Prophylactic mastectomy for women with BRCA1 and BRCA2 mutations - facts and controversy. N Engl J Med 2001;345:207-208.
26. Rowland A, Restant K, Harrop K, Goldblatt J, O'Leary P: Evaluating genetic counseling: client expectations, psychological adjustment and satisfaction with service. J Genet Couns 2005;14:197-206.